In patients with relapsing MS, the transition to cladribine from natalizumab is a safe and effective option that provides sustained disease stability.

A London hospital is to investigate why over half of its patients with multiple sclerosis (MS) who switched from disease modifying therapy Tysabri (natalizumab) to biosimilar Tyruko have had to be ...

The study examined four monoclonal antibodies for MS: natalizumab, ocrelizumab, rituximab and ofatumumab. MS is a disease in which the body's immune system attacks myelin, the fatty white ...